Georgia Attfield
Research Interests
Georgia Attfield has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anne Quinn Young
Multiple Myeloma Research Foundation, Norwalk, USA
1 shared publication- Beth Faiman
Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
1 shared publication Daniel Egbase
VML Health, London, UK
1 shared publication- Faith E. Davies
Perlmutter Cancer Center, NYU Langone Health, New York, NY
1 shared publication Hayley Beer
Peter MacCallum Cancer Centre, Melbourne, Australia
1 shared publicationJ. Blake Bartlett
Janssen Research & Development, Titusville, USA
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Blood Cancer Journal
REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study
Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.
- 14 September 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessREVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study
Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.